• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Immutep Receives Second IND approval for Efti from FDA americanpharmaceuticalreview
    March 10, 2020
    Immutep has announced the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (FDA) for eftilagimod alpha (efti or IMP321).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service